Cargando…
Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics
Cancer multidrug resistance (MDR) could lead to therapeutic failure of chemotherapy and radiotherapy, and has become one of the main obstacles to successful cancer treatment. Some advanced drug delivery platforms, such as inorganic nanocarriers, demonstrate a high potential for cancer theranostic to...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102675/ https://www.ncbi.nlm.nih.gov/pubmed/27980988 http://dx.doi.org/10.1002/advs.201600134 |
_version_ | 1782466467143352320 |
---|---|
author | Lin, Gan Mi, Peng Chu, Chengchao Zhang, Jun Liu, Gang |
author_facet | Lin, Gan Mi, Peng Chu, Chengchao Zhang, Jun Liu, Gang |
author_sort | Lin, Gan |
collection | PubMed |
description | Cancer multidrug resistance (MDR) could lead to therapeutic failure of chemotherapy and radiotherapy, and has become one of the main obstacles to successful cancer treatment. Some advanced drug delivery platforms, such as inorganic nanocarriers, demonstrate a high potential for cancer theranostic to overcome the cancer‐specific limitation of conventional low‐molecular‐weight anticancer agents and imaging probes. Specifically, it could achieve synergetic therapeutic effects, demonstrating stronger killing effects to MDR cancer cells by combining the inorganic nanocarriers with other treatment manners, such as RNA interference and thermal therapy. Moreover, the inorganic nanocarriers could provide imaging functions to help monitor treatment responses, e.g., drug resistance and therapeutic effects, as well as analyze the mechanism of MDR by molecular imaging modalities. In this review, the mechanisms involved in cancer MDR and recent advances of applying inorganic nanocarriers for MDR cancer imaging and therapy are summarized. The inorganic nanocarriers may circumvent cancer MDR for effective therapy and provide a way to track the therapeutic processes for real‐time molecular imaging, demonstrating high performance in studying the interaction of nanocarriers and MDR cancer cells/tissues in laboratory study and further shedding light on elaborate design of nanocarriers that could overcome MDR for clinical translation. |
format | Online Article Text |
id | pubmed-5102675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-51026752016-11-16 Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics Lin, Gan Mi, Peng Chu, Chengchao Zhang, Jun Liu, Gang Adv Sci (Weinh) Reviews Cancer multidrug resistance (MDR) could lead to therapeutic failure of chemotherapy and radiotherapy, and has become one of the main obstacles to successful cancer treatment. Some advanced drug delivery platforms, such as inorganic nanocarriers, demonstrate a high potential for cancer theranostic to overcome the cancer‐specific limitation of conventional low‐molecular‐weight anticancer agents and imaging probes. Specifically, it could achieve synergetic therapeutic effects, demonstrating stronger killing effects to MDR cancer cells by combining the inorganic nanocarriers with other treatment manners, such as RNA interference and thermal therapy. Moreover, the inorganic nanocarriers could provide imaging functions to help monitor treatment responses, e.g., drug resistance and therapeutic effects, as well as analyze the mechanism of MDR by molecular imaging modalities. In this review, the mechanisms involved in cancer MDR and recent advances of applying inorganic nanocarriers for MDR cancer imaging and therapy are summarized. The inorganic nanocarriers may circumvent cancer MDR for effective therapy and provide a way to track the therapeutic processes for real‐time molecular imaging, demonstrating high performance in studying the interaction of nanocarriers and MDR cancer cells/tissues in laboratory study and further shedding light on elaborate design of nanocarriers that could overcome MDR for clinical translation. John Wiley and Sons Inc. 2016-05-30 /pmc/articles/PMC5102675/ /pubmed/27980988 http://dx.doi.org/10.1002/advs.201600134 Text en © 2016 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Lin, Gan Mi, Peng Chu, Chengchao Zhang, Jun Liu, Gang Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics |
title | Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics |
title_full | Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics |
title_fullStr | Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics |
title_full_unstemmed | Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics |
title_short | Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics |
title_sort | inorganic nanocarriers overcoming multidrug resistance for cancer theranostics |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102675/ https://www.ncbi.nlm.nih.gov/pubmed/27980988 http://dx.doi.org/10.1002/advs.201600134 |
work_keys_str_mv | AT lingan inorganicnanocarriersovercomingmultidrugresistanceforcancertheranostics AT mipeng inorganicnanocarriersovercomingmultidrugresistanceforcancertheranostics AT chuchengchao inorganicnanocarriersovercomingmultidrugresistanceforcancertheranostics AT zhangjun inorganicnanocarriersovercomingmultidrugresistanceforcancertheranostics AT liugang inorganicnanocarriersovercomingmultidrugresistanceforcancertheranostics |